This study is not yet accepting patients

A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory Multiple Myeloma

Description

This first-in-human study will evaluate the safety and tolerability of ABBV-467 in adult participants with relapsed/refractory multiple myeloma (MM).

A First In Human Study of the MCL-1 Inhibitor, ABBV-467

Multiple Myeloma (MM) Cancer Relapse/Refractory Multiple Myeloma Neoplasms, Plasma Cell ABBV-467

Open to people ages 18 years and up

Documented diagnosis of multiple myeloma (MM)
Measurable disease defined as at least 1 of the following: serum monoclonal protein ≥ 1g/dL or urine M-protein ≥ 200mg/24 hours
Relapsed after or are refractory or intolerant to all established MM therapies that are known to provide clinical benefit and locally available
Received at least 3 prior lines of therapy including 1 or more immunomodulatory agents, 1 or more proteasome inhibitors, and 1 or more anti-CD38 monoclonal antibodies
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Adequate hematologic, renal and hepatic function
Echocardiogram with ejection fraction ≥ 50% and no other clinically significant findings that would increase the participant's susceptibility to cardiac toxicity

Prior exposure to any targeted MCL-1 inhibitor
Antineoplastic therapy (including any cytotoxic, targeted and/or investigational therapy; but not including corticosteroids), within 28 days or 5 half-lives, whichever is shorter, prior to the first dose of study drug and through the last dose of study drug
Autologous stem cell transplant within 90 days prior to start of study drug
Allogenic stem cell transplant within 180 days prior to start of study drug
History of acute or chronic pancreatitis
Significant unresolved liver disease

UCSD Moores Cancer Center - LaJolla /ID# 210075
La Jolla California 92093 United States
City of Hope /ID# 209786
Duarte California 91010 United States